首页> 外文OA文献 >Misleading Advertising for Antidepressants in Sweden: A Failure of Pharmaceutical Industry Self-Regulation
【2h】

Misleading Advertising for Antidepressants in Sweden: A Failure of Pharmaceutical Industry Self-Regulation

机译:瑞典抗抑郁药的误导性广告:制药业自律失败

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: The alleged efficacy of pharmaceutical industry self-regulation has been used to repudiate increased government oversight over promotional activity. European politicians and industry have cited Sweden as an excellent example of self-regulation based on an ethical code. This paper considers antidepressant advertising in Sweden to uncover the strengths and weaknesses of self-regulation. METHODOLOGY: We analyzed all antidepressant advertisements in the Swedish Medical Journal, 1994-2003. The regulation of these advertisements was analyzed using case reports from self-regulatory bodies. The authors independently reviewed this material to investigate: (1) extent of violative advertising; (2) pattern of code breaches; (3) rate at which the system reacted to violative advertising; (4) prevalence of and oversight over claims regarding antidepressant efficacy and disease causality, and (5) costs for manufactures associated with violative advertising. PRINCIPAL FINDINGS: Self-regulatory bodies identified numerous code breaches. Nonetheless, they failed to protect doctors from unreliable information on antidepressants, since as many as 247 of 722 (34%) advertisements breached the industry code. Self-regulatory bodies repeatedly failed to challenge inflated claims of antidepressant efficacy, lending evidence of lax oversight. On average, 15 weeks elapsed between printing and censure of a wrongful claim, and in 25% of cases 47 weeks or more elapsed. Industry paid roughly €108000 in fines for violative advertising, adding an estimated additional average cost of 11% to each purchased violative advertisement, or amounting to as little as 0.009% of total antidepressant sales of around €1.2 billion. CONCLUSIONS: Lax oversight, combined with lags in the system and low fines for violations, may explain the Swedish system's failure to pressure companies into providing reliable antidepressants information. If these shortcomings prove to be consistent across self-regulatory settings, and if appropriate measures are not taken to amend shortcomings, many countries may want to reconsider the current balance between self-regulation, and legislative control with government oversight.
机译:背景:所谓的制药业自我调节功效已被用于否认政府对促销活动的监督越来越严格。欧洲政客和工业界将瑞典视为基于道德准则的自我监管的极好例子。本文考虑了瑞典的抗抑郁广告,以揭示自我监管的优点和缺点。方法:我们分析了1994-2003年《瑞典医学杂志》中所有抗抑郁药的广告。使用来自自律组织的案例报告分析了这些广告的法规。作者独立审查了该材料,以调查:(1)违规广告的范围; (2)违反代码的模式; (3)系统对违规广告的反应速度; (4)关于抗抑郁药功效和疾病因果关系的主张的普遍性和监督,以及(5)与违法广告有关的制造品的成本。主要发现:自我监管机构发现了许多违反代码的行为。但是,他们未能保护医生免受有关抗抑郁药的不可靠信息的侵害,因为722个广告中有247个(占34%)违反了行业法规。自我调节机构屡屡未能挑战夸张的抗抑郁药功效,这为监督不力提供了证据。从打印到对错误声明的谴责之间,平均经过15周,而在25%的案例中,经过了47周或更长时间。工业界为违规广告支付了大约108000欧元的罚款,估计每个购买的违规广告会增加11%的平均额外费用,或仅占抗抑郁剂总销售额(约12亿欧元)的0.009%。结论:疏忽的监督,加上系统的滞后和对违规行为的低罚款,可能解释了瑞典系统未能迫使公司提供可靠的抗抑郁药信息。如果这些缺点在整个自我监管环境中被证明是一致的,并且如果未采取适当措施来纠正这些缺点,那么许多国家可能希望重新考虑自我监管与立法监督与政府监督之间的当前平衡。

著录项

  • 作者

    Zetterqvist AV; Mulinari S;

  • 作者单位
  • 年度 2013
  • 总页数
  • 原文格式 PDF
  • 正文语种
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号